ARTICLE | Clinical News
Neflamapimod: Ph IIa Study 303 data
January 20, 2017 7:13 PM UTC
The double-blind, U.S. Phase IIa Study 303 in 8 evaluable patients ages 60-85 with mild cognitive impairment (MCI) due to AD or mild AD showed that twice-daily 40 and 125 mg oral neflamapimod improved...
BCIQ Target Profiles